Market Place
Sourcing Support
HCW Biologics Gets FDA Clearance for Phase 1 Clinical Trial
03 Feb 2025 //
GLOBENEWSWIRE
HCW Biologics CEO To Address Key Biotech Industry Challenges
15 Jan 2025 //
GLOBENEWSWIRE
HCW Biologics Inc. Received NASDAQ Staff Determination Letter
23 Dec 2024 //
GLOBENEWSWIRE
HCW Biologics & WY Bio Announce License Agreement for Immunotherapy
18 Nov 2024 //
GLOBENEWSWIRE
HCW Biologics Prices $6.9M Offering & Private Placement
18 Nov 2024 //
GLOBENEWSWIRE
HCW Biologics Reports Q3 2024 Financial Results & Highlights
14 Nov 2024 //
GLOBENEWSWIRE
HCW Biologics Reports Q2 2024 Financial Results And Business Highlights
23 Aug 2024 //
GLOBENEWSWIRE
HCW Biologics Reports Q2 2024 Financial Results And Business Highlights
14 Aug 2024 //
GLOBENEWSWIRE
HCW Biologics Reports Q1 2024 Financial Results, Business Highlights
15 May 2024 //
GLOBENEWSWIRE
HCW Biologics Reports Fourth Quarter 2023 and Fiscal Year End Financial Results
01 Apr 2024 //
GLOBENEWSWIRE
HCW Biologics Reports Third Quarter 2023 Financial Results
14 Nov 2023 //
GLOBENEWSWIRE
Investigator Sponsor of HCW Biologics™ Phase 1 Trial Presented Data of HCW9218
08 Nov 2023 //
GLOBENEWSWIRE
Masonic Cancer, University of Minnesota to Present Data in Human Data Readout
01 Nov 2023 //
GLOBENEWSWIRE
HCW Biologics Reports Second Quarter 2023 Financial Results
11 Aug 2023 //
GLOBENEWSWIRE
HCW Biologics is Granted Third Fundamental Patent
14 Jun 2023 //
GLOBENEWSWIRE
HCW Biologics Reports1Q 2023 FYR And Recent Business Highlights
09 May 2023 //
GLOBENEWSWIRE
HCW Biologics Secures $26.25 M Non-Dilutive Financing With Asset-Backed Dev Loan
27 Apr 2023 //
GLOBENEWSWIRE
HCW Biologics Poster Presentation at AACR Annual Meeting 2023
13 Apr 2023 //
GLOBENEWSWIRE
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
03 Apr 2023 //
GLOBENEWSWIRE
HCW Biologics Reports Fourth Quarter and Full Year 2022 Financial Results
28 Mar 2023 //
GLOBENEWSWIRE
HCW Biologics Enters CRADA with National Cancer Institute
08 Dec 2022 //
GLOBENEWSWIRE
HCW Biologics is Granted Second Fundamental Patent: U.S. Patent
07 Dec 2022 //
GLOBENEWSWIRE
Masonic Cancer Center,University of Minnesota Present Data Poster Presentation
08 Nov 2022 //
GLOBENEWSWIRE
HCW Biologics Reports 3Q2022 Financial Results & Recent Business Highlights
07 Nov 2022 //
GLOBENEWSWIRE
U.S. Patent Issued to HCW Biologics for Foundational Platform Technology
03 Aug 2022 //
GLOBENEWSWIRE
HCW Biologics to Participate in H.C. Wainwright Conference
23 May 2022 //
GLOBENEWSWIRE
HCW Biologics Reports First Quarter 2022 Financial Results
13 May 2022 //
GLOBENEWSWIRE
HCW Biologics to Showcase Two Novel Groups of Fusion Molecules
05 May 2022 //
GLOBENEWSWIRE
HCW Biologics CEO Hing C. Wong, to speak at Cell and Experimental Biology
19 Apr 2022 //
GLOBENEWSWIRE
HCW Biologics Reports Fourth Quarter and Full Year 2021 Financial Results
28 Mar 2022 //
GLOBENEWSWIRE
HCW Biologics to Present at 2022 Virtual Growth Conference by Maxim Group
24 Mar 2022 //
GLOBENEWSWIRE
HCW Biologics’, HCW9218 gets FDA Clearance for Phase 1 Trial in solid tumors
24 Jan 2022 //
GLOBENEWSWIRE
HCW Biologics Says its Lead Candidate Shown to Augment Anti-Tumor Activity
20 Jan 2022 //
GLOBENEWSWIRE
HCW Biologics to Participate in H.C. Wainwright BioConnect Conference
06 Jan 2022 //
GLOBENEWSWIRE
HCW Biologics Reports Q3 Financial Results and Recent Business Highlights
12 Nov 2021 //
GLOBENEWSWIRE
HCWB Stock: The Big FDA News That Has HCW Biologics Booming Today
30 Oct 2021 //
INVESTORPLACE
HCW Biologics Receives FDA Clearance to Proceed with Ph1b Clinical Trial
28 Oct 2021 //
GLOBENEWSWIRE
HCW Biologics Announces Appointment of Two New Members to Board of Directors
27 Oct 2021 //
GLOBENEWSWIRE
HCW Biologics Publishes Scientific Paper for HCW9218 as Cancer Immunotherapeutic
24 Aug 2021 //
GLOBENEWSWIRE
HCW Biologics Reports Second Quarter Financial Results
13 Aug 2021 //
GLOBENEWS WIRE
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
22 Jul 2021 //
GLOBENEWSWIRE
HCW Biologics Inc. Announces Closing of $56.0 Million Initial Public Offering
22 Jul 2021 //
GLOBENEWSWIRE
